These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
    Author: Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I.
    Journal: Neurosurg Clin N Am; 2012 Apr; 23(2):307-22, ix. PubMed ID: 22440874.
    Abstract:
    This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the standard of care for the modern treatment of stage IV glioblastoma multiforme since its approval in 2005. Yet despite its improvements from previous therapies, median survival remains approximately 15 months, with a 2-year survival rate of 8% to 26%. The mechanism of action of this chemotherapeutic agent, conferred advantages and limitations, treatment resistance and rescue, and potential targets of future research are discussed.
    [Abstract] [Full Text] [Related] [New Search]